雷贝拉唑治疗胃食管反流性疾病的疗效及价值  

Clinical effect and value of Bella in treatment of gastroesophageal reflux disease

作　　者：谢巧玉[1] 林霖[1] 

机构地区：[1]广东省梅州市人民医院消化二科,广东梅州514031

出　　处：《中国医药科学》2017年第2期50-52,共3页China Medicine And Pharmacy

摘　　要：目的观察分析雷贝拉唑治疗胃食管反流性疾病的临床效果及价值。方法选取2015年3月~2016年3月我院收治的92例胃食管反流性疾病的患者为研究对象,依据随机数表法将92例患者随机分为研究组和对照组,各46例。对照组给予奥美拉唑胶囊20mg口服,2次/d;研究组给予雷贝拉唑肠溶胶囊10mg口服,2次/d。两组治疗8周后比较临床症状及内窥镜下所见食管黏膜的改善情况。结果研究组对临床症状及食管黏膜损伤的治疗效果均优于对照组,两组之间差异有统计学意义(P<0.05)。两组患者疗程中均未出现明显不良反应且治疗前后血、尿常规及生化综合检查均未见明显异常。结论在胃食管反流性疾病的治疗方面,雷贝拉唑临床效果可靠且安全,值得临床推广和应用。Objective To observe and analyze the clinical effect and value of ray Bella with the treatment of gastroesophageal reflux disease. Methods 92 cases of gastroesophageal reflux disease patients cured in our hospital from March 2015 to March 2016 were selected as the research objects. According to the random number table method, the patients were randomly divided into study group and control group, 46 cases in each. Patients in control group were given omeprazole capsule 20rag, oral bid, and patients in study group were given ray Bella with enteric capsule lOmg, oral bid. The clinical symptoms and endoscopic findings improved the esophageal mucosa after 8 weeks of treatment were compared. Results The study group was better than the control group in the treatment of clinical symptoms and esophageal mucosal injury, There were significant differences between the two groups （P 〈 0.05）. In the course of the two groups of patients had no obvious adverse reactions before and after treatment of blood, urine routine and biochemical examination showed no obvious abnormalities. Conclusion In the treatment of gastroesophageal reflux disease, the clinical efficacy of Bella is reliable and safe, and it isworthy of clinical promotion and application.

关 键 词：雷贝拉唑 胃食管反流性疾病 临床效果 

分 类 号：R571[医药卫生—消化系统]